Country for PR: China
Contributor: PR Newswire Asia (China)
Friday, March 20 2020 - 16:09
Prof. Oliver Sartor Joins Clarity's Advisory Board
SYDNEY, March 20, 2020 /PRNewswire-AsiaNet/ --

Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment 
of serious disease, is pleased to announce that Prof. Oliver Sartor has joined 
Clarity's Advisory Board.

Prof. Sartor is a medical oncologist and an internationally recognised expert 
in prostate cancer. He is the Laborde Professor for Cancer Research, Medical 
Director of the Tulane Cancer Center, and Assistant Dean for Oncology at Tulane 
University School of Medicine in New Orleans, Louisiana.

Prof. Sartor has published over 400 peer reviewed publications and has over 
25,000 citations. He has lectured widely, giving lectures on prostate cancer in 
34 countries. Prof. Sartor has been a principal or co-principal investigator on 
multiple national and international advanced prostate cancer trials including 
those which were pivotal for FDA approval for samarium-153 EDTMP, cabazitaxel, 
and radium-223. He is medical oncology chair of the Genitourinary committee of 
NRG Oncology. 

He is a past member of the Board of Scientific Counselors (Clinical Sciences 
and Epidemiology) at the National Cancer Institute and previously served as 
Chairman of the Prostate Cancer Integration Panel for the U.S. Department of 
Defense. He has chaired 5 Data Monitoring Committees for Phase III trials that 
lead to FDA approval.

Prof. Sartor received his MD from Tulane University with honours in 1982. After 
his internship at the University of Pennsylvania, he trained in Internal 
Medicine at Tulane Medical School. After completing his fellowship at the NCI 
in Bethesda, Maryland in 1989, he served until 1993 as a Senior Investigator at 
the NCI with a focus on novel therapeutics for advanced prostate cancer 

Prof. Sartor commented on his appointment: "Clarity has made significant 
progress in developing its copper-based product platform in recent years. I am 
excited to join Clarity's Advisory Board as I have for some time seen the 
benefits radiopharmaceuticals bring to cancer therapy, especially in prostate 
cancer. I'm very much looking forward to working with the team and using the 
unique and favourable characteristics of copper to address the current 
limitations of radiopharmaceuticals in the treatment of cancer, with a view of 
improving treatment outcomes for cancer patients around the world."

Clarity's Executive Chairman Dr. Alan Taylor said: "We are honoured to welcome 
Prof. Sartor to our Advisory Board at this exciting time when two of our 
products that have blockbuster potential of treating prostate cancer, 
SAR-bisPSMA and SAR-BBN, are entering clinical trials. His unique expertise in 
this field and extensive experience in leading prostate cancer trials will be 
invaluable to the timely and successful development of these products. We are 
looking forward to working closely with Prof. Sartor as we progress our goal of 
developing safer and more effective treatments for children and adults with 

About Clarity

Clarity is a personalised medicine company focused on the treatment of serious 
diseases. The Company is a leader in innovative radiopharmaceuticals, 
developing targeted therapies for the treatment of cancer and other serious 
diseases in adults and children. 


Dr Alan Taylor
Executive Chairman

SOURCE:Clarity Pharmaceuticals